A Highly Potent Human sRAGE Protein for Treating Vascular Disease, Injury, or Inflammation
Posted Feb 22 2012 7:00pm
Description of Invention: The receptor for advanced glycation end products (RAGE) is a cell surface protein that triggers signaling pathways leading to inflammation. RAGE-stimulated inflammation can contribute to adverse vascular conditions, such as atherosclerosis and restenosis. The soluble version of RAGE (sRAGE) binds the same target molecules (advanced glycation end products), but cannot activate inflammatory signaling pathways. For this reason, sRAGE is thought to act as a decoy for RAGE. sRAGE reduces inflammation and pathogenic consequences associated with RAGE signaling. The administration of sRAGE has been used to treat atherosclerosis and arterial restenosis in animal models. The inventors established a way to produce human sRAGE with more than 1000-fold greater potency than current methods. Production of full length human sRAGE in cultured mammalian cells enables addition of mammalian post-translational modifications that dramatically enhance potency. This invention covers methods of production, the resulting modified sRAGE molecules, and methods of using this highly potent sRAGE for treating adverse vascular conditions.
Prevention of vascular inflammation
Treating vascular injuries due to angioplasty or traumatic injury
Treating vascular complications of Diabetes mellitus
Alzheimer’s Disease treatment based on amyloid-beta protein binding
Greater than 1000-fold increased potency over sRAGE produced in insect cells
Readily scalable production as a recombinant protein secreted from CHO cells
Simple affinity purification method
In vitro data available
In vivo data available (animal)
Inventors: Li Lin (NIA) Rui-ping Xiao (NIA) Wen Wei (NIA) Sungha Park (NIA) Mark I Talan (NIA)
Collaborative Research Opportunity: The National Institute on Aging, Laboratory of Cardiovascular Science, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize sRAGE. For collaboration opportunities, please contact Vio Conley, M.S. at email@example.com .
For Licensing Information Please Contact: Betty Tong Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-594-6565 Fax: 301-402-0220